AIM Immunotech vs Ibio
AIM Immunotech and Ibio are similar in size: $88,000 and $100,000 of revenue in their latest fiscal years. AIM Immunotech grew faster (-48.2% against -75.0%). AIM Immunotech kept more of each dollar of sales as profit: a net margin of -15861.4% against -33044.0%.
| Latest fiscal year | AIM ImmunotechAIM, 2025 | IbioIBIO, 2026 |
|---|---|---|
| Revenue | $88,000 | $100,000 |
| Revenue growth | -48.2% | -75.0% |
| Net income | −$14.0m | −$33.0m |
| Operating margin | -13254.5% | -35141.0% |
| Net margin | -15861.4% | -33044.0% |
| Return on equity | — | -65.7% |
| Free cash flow | −$11.0m | −$23.8m |
| Cash | $3.0m | $56.4m |
| Total debt | $8.0m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 23 |
| Market value | $4.7m | $45.5m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 6 buys, 0 sales | 4 buys, 0 sales |